KRAS and colorectal carcinoma: Mutations in the KRAS gene, present in approximately 40–50% of all CRC cases, lead to excessive activation of the RAS/RAF/MEK/ERK signaling pathway, promoting cell proliferation and inhibiting apoptosis [7].